An interventional study of Cognitive Assessment, Cytokine dosage in Cognitive Impairment, Haematological Malignancy and Chemo-brain, sponsored by Ospedale San Carlo Borromeo. Status unknown at 1 site in Italy. Open to participants aged 70 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-12-17.
Sponsored by Ospedale San Carlo Borromeo · Not applicable, Interventional, and Diagnostic
BACKGROUND Neurocognitive symptoms have a high prevalence in cancer patients, resulting in a significant impact on daily life and tolerance to therapy. It's estimated that about 30% of cancer patients present a cognitive impairment before treatment, about 75% present this cognitive impairment during the treatment, and about 35% continue to present cognitive difficulties in the following months/years.
There is growing evidence that cognitive symptoms have a biological mechanism linked to the activation of immunological cytokines that exert important effects on the brain functions. For example, interferon α is known to increase the levels of IL-1, IL-6 and TNF-α, and this increase is associated with memory deficits, executive function and mood alterations.
A neurotoxic action induced by cytokines has been demonstrated both in the early stages of the tumor and after chemotherapy.
Several imaging studies suggest that the cognitive impairment pattern in cancer patients, during the treatment and in remission, is related to structural and functional brain changes.
Longitudinal studies in women with breast cancer treated with chemoterapy have shown a reduction in the volume of cerebral gray matter, mainly in the bilateral frontal cortex and hippocampus. In parallel, diffusion tensor imaging studies have shown an alteration of the integrity of the frontal, parietal and occipital cerebral white matter, demyelination and axonal degeneration processes. Finally, functional magnetic resonance studies in cancer patients have shown alterations in the connectivity of the default mode network compared to control subjects.
Studies carried out to date, show a prevalent impairment of executive functions and working memory. Cognitive impairment has been studied mainly as a possible adverse effect in women treated with chemotherapy for breast cancer, while there are few studies in the literature on patients with haematological malignancies.
STUDY DESIGN The study is targeted to patients ages ≥ 70 years, whith haematological malignancy, who need to start a treatment within 3 months.
Once the eligibility criteria have been assessed, the hematologist proposes the enrollment in the study. Once the patient's informed consent has been acquired, a neurological examination is carried out, functional tests required by the protocol are administered. The patient begins, as per clinical practice, the treatment provided for his/her haematological malignancy. Test's evaluation is repeated at 6 months and 12 months after the enrollment. In conjunction with neurological tests, will be performed a venipuncture as per clinical practice, and a blood sample is taken to measure the cytokines involved in inflammatory processes. It is expected that a patient can perform up to a maximum of 3 blood samples for the biological study.
STATISTICAL ANALYSIS This is a non-pharmacological, prospective, uncontrolled, open-label single-center interventional pilot study, aimed to describ the progress of cognitive function under treatment for haematological disease.
Due to the pilot and exploratory nature of the study and the substantial absence of a specific literature relating to the elderly onco-haematological patient, it is not believed that the conditions exist to be able to formally define the size of the sample. The sample size is arbitrarily fixed at 60 patients. The observation time will be 12 months from enrollment.
9,365 studies on the registry are indexed under Neoplasms; 2,486 are open to participants now.
This study's planned enrollment of 60 is above the median of 50 across 7,250 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Ospedale San Carlo Borromeo is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
patients ≥ 70 years, whith haematological malignancy, who need to start a treatment within 3 months
Other: Cognitive Assessment, Cytokine dosage
Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
Evaluation of the score trend obtained with the Mini-mental test (MMSE)
MMSE score at 12 months will be compared with the MMSE at enrollment.
Time frame: 12 months from the enrollment
Activities of daily living (ADL) score
ADL at 12 months will be compared with ADL at enrollment.
Time frame: 12 months from the enrollment
Instrumental activities of daily living (IADL) score
IADL at 12 months will be compared with IADL at enrollment.
Time frame: 12 months from the enrollment
Charlson comorbidity index
Charlson comorbidity index at 12 months will be compared with Charlson comorbidity index at enrollment.
Time frame: 12 months from the enrollment
CDT (clock drawing test)
CDT at 12 months will be compared with CDT st enrollment.
Time frame: 12 months from the enrollment
FAB (frontal assessment battery)
FAB at 12 months will be compared with FAB at enrollment.
Time frame: 12 months from the enrollment
Digit Span
Digit Span at 12 months will be compared with Digit Span at enrollment.
Time frame: 12 months from the enrollment
CorsiTest
Corsi Test at 12 months will be compared with Corsi Test at enrollment.
Time frame: 12 months from the enrollment
STAI-Y test
STAI-Y test at 12 months will be compared with STAI-Y test at enrollment.
Time frame: 12 months from the enrollment
Serum IL-1 levels (pg/ml)
Correlations of IL-1 levels with cognitive functions.
Time frame: 12 months from the enrollment
Serum IL-2 levels (pg/ml)
Correlations of IL-2 levels with cognitive functions.
Time frame: 12 months from the enrollment
Serum IL-6 levels (pg/ml)
Correlations of IL-6 levels with cognitive functions.
Time frame: 12 months from the enrollment
Serum TNFα levels (pg/ml)
Correlations of TNFα levels with cognitive functions.
Time frame: 12 months from the enrollment
Serum IL-4 levels (pg/ml)
Correlations of IL-4 levels with cognitive functions.
Time frame: 12 months from the enrollment
Serum IL-10 levels (pg/ml)
Correlations of IL-10 levels with cognitive functions.
Time frame: 12 months from the enrollment
This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ospedale San Carlo Borromeo